Good points :
"The NIH and NIAID knows it works against many variants to a degree other drugs cannot. They also know from the testing on the 20 other viral strains..."
IMO the most important point in the PR is Brilacidin demonstrated an inhibitory effect on all the Covid variants tested including MERS and SARS, and to the best of my knowledge it is the only antiviral reported to achieve such a broad antiviral effect. In addition it has been shown to have similar effects against 20 pathogenic viruses.
From todays PR:
"Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin)."
I hope they will test Brilacidin against the new variants as they seem to be resistant to a degree against natural and vaccine immune protection.
"BA.4 and BA.5 then evolved to dodge the enormous amount of immunity induced by the original Omicron — and over the last month, their share of U.S. cases has been roughly doubling every seven days, signaling exponential growth. At the same time, U.S. reinfection rates appear to be rising. By July, BA.4 and BA.5 will likely be dominant nationwide."
Covid antivirals seem to be most effective early in the disease. IMO the next focus for Brilacidin should be other delivery methods; such as,IM depo injections,inhaled and oral. The governments biodefense labs seem to be interested in Brilacidin for Covid. Hopefully we can find funding to make Brilacidin an important treatment for Covid mutations which seem to be recurring every few months.